Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076794 | 1.00 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL844213 | 0.94 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL844212 | 0.94 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL30536457 | 0.94 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL29055719 | 0.94 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL844132 | 0.94 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL13765315 | 0.92 | MAP2K1 (0.45) | MAP2K1ESR1S1PR1S1PR3MAPK1 | |
| SCHEMBL13950576 | 0.92 | MAP2K1 (0.45) | MAP2K1ESR1S1PR1S1PR3MAPK1 | |
| SCHEMBL13950330 | 0.91 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 | |
| SCHEMBL13765317 | 0.91 | MAP2K1 (0.49) | MAP2K1ESR1ESR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | MAP2K1 35/4885ESR1 1621/4885ESR2 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.